Return back to Faculty Listing
 Craig R. Rush, Ph.D.
(University of Vermont, 1992)
Professor Department of Behavioral Science,
Department of Psychiatry, and
Department of Psychology
University of Kentucky
Lexington, KY 40536-0086
Office Phone: (859) 323-6130
Lab: (859) 257-5384
Office FAX: (859) 323-5350
Lab FAX: (859) 257-7684
crush2@uky.edu
Research Description
Dr. Rush’s research interests are primarily focused on identifying putative pharmacotherapies for the management of stimulant dependence. Dr. Rush uses the principles of pharmacology and behavioral analysis to determine the effects of commonly abused stimulants alone and following pretreatment with the putative pharmacotherapy. Special emphasis is given to putative stimulant antagonists as well as agonist replacement therapies. Currently, there are four funded projects underway in Dr. Rush’s laboratory. The first project is investigating the neuropharmacology of stimulant abuse in humans. Specifically, this project is attempting to elucidate the role of dopamine, a chemical in the brain, in mediating the effects of stimulants in humans. They use a human drug-discrimination procedure and subject-rated drug-effect questionnaires to assess drug effects in volunteers with recent histories of stimulant use. This project has important implications for validating animal models and for understanding the neuropharmacology of stimulant abuse in humans. Two projects are investigating the efficacy of novel antipsychotics as putative pharmacotherapies for stimulant dependence. The final project is attempting to elucidate to identify the behavioral mechanism that mediates the clinical effects of agonist replacement therapies for cocaine dependence. This project will also determine the efficacy of novel agonist replacement therapies. These projects could have implications for the treatment of methamphetamine and cocaine dependence.
Current Research Funding
Principal Investigator, Human Cocaine Discrimination (2R01 DA 010325). National Institute on Drug Abuse (08/01/03 – 7/31/07).
Principal Investigator, Preventing Cocaine Relapse: Developing Pharmacotherapies (R01 DA 020429). National Institute on Drug Abuse (09/27/05 – 8/31/09).
Principal Investigator, Stimulant Abuse Pharmacotherapy: Novel Antipsychotics (2R01 DA 017711), National Institute on Drug Abuse (08/01/05 - 04/30/10).
Principal Investigator, Agonist Replacement Therapy for Cocaine Dependence: Identifying Novel Medications (R01 DA021155). National Institute on Drug Abuse (06/01/06 - 03/31/10).
Representative Publications
Stoops, W.W., Lile, J.A., Glaser, P.E.A. and Rush, C.R. (2006). A low dose of aripirprazole attenuates some of the subject-rated effects of d-amphetamine. Drug and Alcohol Dependence, 84: 206-209
Lile, J.A., Stoops, W.W., Vansickel, A.R., Glaser, P.E.A., Hays, L.R., and Rush, C.R. (2005). Aripiprazole attenuates the discriminative-stimulus effects of d-amphetamine in humans. Neuropsychopharmacology, 30: 2103-2114.
Rush , C.R., Higgins, S.T., Vansickle, A.R., Stoops, W.W., Lile, J.A., and Glaser, P.E.A. (2005). Methylphenidate increases cigarette smoking. Psychopharmacology, 181:781-789.
Stoops W.W., Lile J.A., Fillmore M.T., Glaser P.E.A., Rush C.R. (2005). Reinforcing effects of methylphenidate: Influence of dose and behavioral demands following drug administration. Psychopharmacology, 177:349-355.
Stoops, W.W., Lile, J.A., Fillmore, M.T., Glaser, P.E.A. and Rush, C.R. (2005). Reinforcing effiects of modafinil: Influence of dose and behavioral demands following drug administration. Psychopharmacology, 182: 186-193.
Stoops, W.W., Lile, J.A., Glaser, P.E.A. and Rush, C.R., (2005). Discriminative- stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Experimental and Clinical Psychopharmacology, 13: 56-64.
Rush, C.R., Stoops, W.W., Wagner, F.P., Hays, L.R. and Glaser, P.E.A. (2004). Alprazolam attenuates the behavioral effects of d-amphetamine in humans. Journal of Clinical Psychopharmacology, 24: 410-420.
Lile, J.A., Stoops, W.W., Allen, T.S., Glaser, P.E.A., Hays, L.R., and Rush, C.R. (2004). Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans. Psychopharmacology, 171: 441-449.
Rush, C.R., Stoops, W.W., Hays, L.R., Glaser, P.E.A., and Hays, L.S. (2003). Risperidone attenuates the discriminative-stimulus of d-amphetamine in humans. Journal of Pharmacology and Experimental Therapeutics, 306: 195-204.
Laboratory of Human Behavioral Pharmacology
|
